ATYR Earnings Date: Nov 5, 2026 (Estimated) — aTyr Pharma, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ATYR's next earnings date?
aTyr Pharma, Inc. (ATYR) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$4.00 on revenue of $2.5M.
How did ATYR do in its last earnings report?
In its most recent report on Aug 7, 2026 (Q2 2026), aTyr Pharma, Inc. posted EPS of -$0.11 versus the -$0.12 estimate, a beat of 8.3%. Revenue was $0. The stock's 1-day post-earnings move was +3.4%.
How much does ATYR stock move after earnings?
ATYR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.5% (up or down) in the day after earnings.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Q2 2026 | -0.12 | -0.11 | +8.33% | $0 | ✅ Beat | +3.42% | +9.29% | -6.01% |
| 2026-05-15 | Q1 2026 | -0.15 | -0.11 | +26.67% | $0 | ✅ Beat | -9.98% | -5.61% | -20.83% |
| 2026-03-05 | Q4 2025 | -0.18 | -0.14 | +22.22% | $0 | ✅ Beat | -8.68% | -3.86% | -8.68% |
| 2025-11-06 | Q3 2025 | -0.19 | -0.26 | -36.84% | $0 | ❌ Miss | +6.05% | -7.39% | +5.44% |
| 2025-03-13 | Q4 2024 | -0.23 | -0.18 | +21.74% | $0 | ✅ Beat | -0.50% | -5.76% | -25.56% |
| 2024-11-07 | Q3 2024 | -0.22 | -0.23 | -4.55% | $0 | ❌ Miss | +0.65% | +2.90% | +13.87% |
| 2024-08-13 | Q2 2024 | -0.25 | -0.23 | +8.00% | $0 | ✅ Beat | +6.32% | +6.90% | +7.47% |
| 2024-05-02 | Q1 2024 | -0.24 | -0.23 | +4.17% | $235,000 | ✅ Beat | +0.63% | +7.50% | +15.63% |
Showing last 8 quarters.